Adagene Inc
Company Profile
Business description
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
Contact
Xinghu Street, Suzhou Industrial Park
4th Floor, Building C14, No. 218
Jiangsu Province
Suzhou215123
CHNT: +86 51287773632
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
128
Stocks News & Analysis
stocks
3 charts on Anthropic’s historic IPO filing
stocks
Weight loss drugs not an existential threat to undervalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,971.40 | 2.60 | 0.03% |
| CAC 40 | 7,886.96 | 0.18 | -0.00% |
| DAX 40 | 25,704.02 | 113.25 | 0.44% |
| Dow JONES (US) | 52,435.55 | 57.98 | 0.11% |
| FTSE 100 | 10,694.50 | 7.96 | 0.07% |
| HKSE | 23,094.83 | 53.51 | 0.23% |
| NASDAQ | 26,500.75 | 22.94 | 0.09% |
| Nikkei 225 | 63,954.19 | 685.82 | 1.08% |
| NZX 50 Index | 13,691.33 | 11.06 | 0.08% |
| S&P 500 | 7,738.30 | 15.70 | 0.20% |
| S&P/ASX 200 | 8,847.30 | 2.80 | -0.03% |
| SSE Composite Index | 3,681.47 | 33.17 | 0.91% |